Prime Medicine

PRME

Market cap $632M

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D.

Prime Medicine, Inc. ( PRME ) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST Company Participants Gregory Dearborn Allan Reine - CEO & Director Mohammed Asmal Conference Call Participants Michael Schilsky Maurice Raycroft - Jefferies LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Troy Langford David Nierengarten - Wedbush Securities Inc., Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Presentation Gregory Dearborn Good morning, everyone, and welcome to Prime Medicine's virtual event to discuss our liver disease franchise and strategy focused on Wilson disease.

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D.

-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 --  -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 --

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.44 per share a year ago.

-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 --  -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 --

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime's corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the company's efforts to expand the reach of Prime Editing through strategic partnerships and collaborations.

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson's Disease.

CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C.

Prime Medicine, Inc. (NASDAQ:PRME ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Okay. Well, thanks, everybody, for joining us.